No, Ajovy Cannot Be Given Every 6 Weeks
Ajovy (fremanezumab) is FDA-approved for only two dosing regimens: 225 mg monthly (every 4 weeks) or 675 mg quarterly (every 3 months), and a 6-week dosing interval is not an approved or studied option 1.
FDA-Approved Dosing Options
The FDA label explicitly states two subcutaneous dosing options 1:
- Monthly dosing: 225 mg every 4 weeks (28 days)
- Quarterly dosing: 675 mg every 3 months (administered as three consecutive 225 mg injections)
When switching between these regimens, you should administer the first dose of the new regimen on the next scheduled date of the previous regimen 1.
Why 6-Week Dosing Is Not Supported
The pharmacokinetic profile of fremanezumab does not support a 6-week interval:
- Terminal half-life: Approximately 29-30 days in both adults and pediatric patients 2, 3
- Time to maximum concentration: Median of 5 days 2
- The drug follows a two-compartment model with first-order absorption, and body weight is the primary determinant of exposure 3
These pharmacokinetic parameters were specifically studied to establish the monthly and quarterly dosing regimens that maintain therapeutic drug levels. A 6-week interval would fall between these validated schedules and has not been evaluated for efficacy or safety.
Clinical Trial Evidence
All pivotal trials establishing fremanezumab's efficacy used either monthly or quarterly dosing 4, 5:
- The SPACE trial (pediatric approval) used weight-based monthly dosing
- Phase 2b/3 trials in episodic migraine demonstrated significant reductions in monthly migraine days with both approved regimens
- Real-world effectiveness studies confirm sustained benefit with monthly or quarterly administration 6, 7
Practical Considerations
If a patient misses a dose, the FDA label provides clear guidance: administer as soon as possible, then schedule subsequent doses from the date of that last dose 1. This maintains either a monthly or quarterly schedule—not an arbitrary 6-week interval.
The quarterly option (675 mg every 3 months) may be preferable for patients seeking less frequent administration, as it provides bioequivalent exposure to monthly dosing while reducing injection frequency 2, 8.
Using an unapproved 6-week dosing schedule would constitute off-label use without supporting pharmacokinetic, efficacy, or safety data, potentially leading to subtherapeutic drug levels and treatment failure.